- Home
- VMO vs CSTL Comparison
VMO vs CSTL Comparison
Compare VMO & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMO | CSTL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 673.7M | 722.8M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VMO | CSTL |
|---|---|---|
| Price | $9.88 | $23.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 246.9K | ★ 334.4K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | N/A | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $8.93 | $14.59 |
| 52 Week High | $10.10 | $44.28 |
Technical Indicators
Market Signals| Indicator | VMO | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 57.31 |
| Support Level | $9.83 | $23.21 |
| Resistance Level | $9.92 | $24.49 |
| Average True Range (ATR) | 0.05 | 0.99 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 33.88 | 62.04 |
Price Performance
Historical ComparisonAbout VMO Invesco Municipal Opportunity Trust
Invesco Municipal Opportunity Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.